1ygd Citations

Crystallographic evidence for a new ensemble of ligand-induced allosteric transitions in hemoglobin: the T-to-T(high) quaternary transitions.

Biochemistry 44 6101-21 (2005)

Abstract

A detailed description of hemoglobin cooperativity requires knowledge of the dimer-dimer interactions responsible for the low ligand affinity of the quaternary-T tetramer, the "quaternary-T constraints", along with stereochemical pathways that specify how ligand binding disrupts these quaternary constraints. The recent mutagenic screen of Noble et al. [Noble, R. W., et al. (2001) Biochemistry 40, 12357-12368] has identified the major region of quaternary constraint to be a cluster of residues at the alpha1beta2 interface that is centered at Trp37beta. In this paper, crystallographic studies are presented for most of the mutant hemoglobins studied by Noble et al. These crystallographic experiments identify structural transitions-referred to as T-to-T(High) transitions-between the quaternary-T structure of wild-type deoxyhemoglobin and an ensemble of related T-like quaternary structures that are induced by some mutations in the Trp37beta cluster and/or by exposing crystals of wild-type or mutant deoxyhemoglobins to oxygen. The T-to-T(High) quaternary transitions consist of a rotation of the alpha1beta1 dimer relative to the alpha2beta2 dimer as well as a coupled alphabeta dimer bending component that consists of a small rotation of the alpha1 subunit relative to the beta1 subunit (and a symmetry related rotation of the alpha2 subunit relative to the beta2 subunit). In addition, differences in subunit tertiary structure associated with the T-to-T(High) transitions suggest two stereochemical pathways (one associated with the alpha subunits and one associated with the betasubunits) by which ligand binding specifically disrupts quaternary constraints in the Trp37beta cluster. In the alpha subunits, ligand binding induces a shift of the heme iron producing tension in a chain of covalent bonds that extends from the Fe-N(epsilon)(2)His(F8)alpha1 bond to the peptide backbone bonds of residues His87(F8)alpha1 and Ala88(F9)alpha1. This tension induces an alpha-to-pi transition in the COOH-terminal end of the F-helix that shifts the beta-carbon of Ala88alpha1 by approximately 1.5 A directly into the side chain of Tyr140alpha1 (a key residue in the Trp37beta2 cluster). Collectively these structural changes constitute a relatively short pathway by which ligand binding forces Tyr140alpha1 into the alpha1beta2 interface disrupting quaternary constraints associated with the Trp37beta2 cluster. In the beta subunits, our analysis suggests a more extended energy transduction pathway in which ligand-induced beta1-heme movement triggers tertiary changes in the beta1 subunit that promote alpha1beta1 dimer bending that disrupts quaternary constraints in the Trp37beta2 cluster at the alpha1beta2 interface.

Reviews citing this publication (9)

  1. New look at hemoglobin allostery. Yuan Y, Tam MF, Simplaceanu V, Ho C. Chem Rev 115 1702-1724 (2015)
  2. Allosteric hemoglobin assembly: diversity and similarity. Royer WE, Zhu H, Gorr TA, Flores JF, Knapp JE. J Biol Chem 280 27477-27480 (2005)
  3. Protein dynamics explain the allosteric behaviors of hemoglobin. Yonetani T, Laberge M. Biochim Biophys Acta 1784 1146-1158 (2008)
  4. Hemoglobin: Structure, Function and Allostery. Ahmed MH, Ghatge MS, Safo MK. Subcell Biochem 94 345-382 (2020)
  5. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Safo MK, Kato GJ. Hematol Oncol Clin North Am 28 217-231 (2014)
  6. How does hemoglobin generate such diverse functionality of physiological relevance? Yonetani T, Kanaori K. Biochim Biophys Acta 1834 1873-1884 (2013)
  7. Snails In Silico: A Review of Computational Studies on the Conopeptides. Mansbach RA, Travers T, McMahon BH, Fair JM, Gnanakaran S. Mar Drugs 17 E145 (2019)
  8. Crystallographic evidence for dioxygen interactions with iron proteins. Carrondo MA, Bento I, Matias PM, Lindley PF. J Biol Inorg Chem 12 429-442 (2007)
  9. Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. Pagare PP, Rastegar A, Abdulmalik O, Omar AM, Zhang Y, Fleischman A, Safo MK. Expert Opin Ther Pat 32 115-130 (2022)

Articles citing this publication (29)